Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;68(8):e29084.
doi: 10.1002/pbc.29084. Epub 2021 Apr 24.

Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma

Marissa A Just  1 , David Van Mater  1 , Lars M Wagner  1
Affiliations
Review

Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma

Marissa A Just et al. Pediatr Blood Cancer. 2021 Aug.

Abstract

Adjuvant chemotherapy for osteosarcoma and Ewing sarcoma consists of conventional cytotoxic regimens that have changed little over the past decades. There is an urgent need for agents that are more effective and have less long-term toxicity. Receptor tyrosine kinases regulate cell growth and proliferation of these tumors, and small-molecule inhibitors for many of these kinases are now available. In this article, we review published phase II trials for patients with recurrent disease and highlight the pathways targeted by available agents, as well as the toxicity and efficacy results seen to date. We also discuss the difficulties in identifying biomarkers to facilitate rational patient selection, as well as published and proposed strategies for how these inhibitors can be combined with conventional chemotherapy or other targeted agents. It is hoped future trials can capitalize on this growing experience to optimize the use of this exciting class of agents.

Keywords: Ewing sarcoma; adolescent and young adult oncology; osteosarcoma; pediatric oncology; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors have no conflicts of interest to disclose.

References

    1. Reed DR, Hayashi M, Wagner L, et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017;123(12):2206–2218. - PMC - PubMed
    1. Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J. 2018;4:12. - PMC - PubMed
    1. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036–3046. - PubMed
    1. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396–1408. - PMC - PubMed
    1. Leavey P, Krailo M, DuBois S, et al. A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide (VTC) to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma – a report from the Children’s Oncology Group. 2019 Connective Tissue Oncology Society Annual Meeting; November 16, 2019; Tokyo, Japan.

Publication types

MeSH terms

Substances